Genprex Inc. (GNPX) and ArQule Inc. (NASDAQ:ARQL) Comparison side by side

This is therefore a contrasting of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in Genprex Inc. (NASDAQ:GNPX) and ArQule Inc. (NASDAQ:ARQL). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genprex Inc. N/A 0.00 6.26M -0.97 0.00
ArQule Inc. 9 -3.39 101.44M -0.17 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Genprex Inc. and ArQule Inc.


Table 2 represents Genprex Inc. (NASDAQ:GNPX) and ArQule Inc. (NASDAQ:ARQL)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Genprex Inc. 1,462,275,169.35% -141.2% -136%
ArQule Inc. 1,142,342,342.34% -29.1% -20.9%


Genprex Inc.’s Current Ratio is 30.5 while its Quick Ratio is 30.5. On the competitive side is, ArQule Inc. which has a 6.5 Current Ratio and a 6.5 Quick Ratio. Genprex Inc. is better positioned to pay off short and long-term obligations compared to ArQule Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Genprex Inc. and ArQule Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Genprex Inc. 0 0 0 0.00
ArQule Inc. 0 0 6 3.00

Competitively the average target price of ArQule Inc. is $13.83, which is potential 48.71% upside.

Institutional and Insider Ownership

Genprex Inc. and ArQule Inc. has shares owned by institutional investors as follows: 13.1% and 77.4%. 51.7% are Genprex Inc.’s share owned by insiders. On the other hand, insiders owned about 1% of ArQule Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Genprex Inc. -9.79% -15.91% -43.3% -32.5% -67.57% -9.79%
ArQule Inc. -3.9% -9.83% 58.9% 183.43% 99.41% 264.26%

For the past year Genprex Inc. had bearish trend while ArQule Inc. had bullish trend.


ArQule Inc. beats Genprex Inc. on 7 of the 11 factors.

Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. Genprex, Inc. was founded in 2009 and is based in Austin, Texas.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of BrutonÂ’s tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.